MedTrace Logo

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

NCT01481194 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2019-03-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination treatment of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide in newly diagnosed multiple myeloma patients.

Conditions

Interventions

DRUG

Doxorubicin

50 mg/m2 IV on day 1 of a 21-day cycle

DRUG

Bortezomib

1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle

DRUG

Lenalidomide

15 mg orally on days 1-14 of a 21-day cycle

DRUG

Dexamethasone

20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle

DRUG

Cyclophosphamide

750 mg/m2 IV on day 1 of a 21-day cycle

Sponsors & Collaborators

  • The University of Hong Kong

    collaborator OTHER

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Torben Plesner, DMSc · Vejle Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-05-31
Completion
2018-08-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01481194 on ClinicalTrials.gov